Fructose diet alleviates acetaminophen-induced hepatotoxicity in mice by Sungjoon Cho (4385851)

“…Fructose-treated mice exhibited (~1.5 fold) higher basal glutathione levels and (~2 fold) lower basal (mRNA and activity) levels of Cyp1a2 and Cyp2e1, suggesting decreased bioactivation of APAP and increased detoxification of toxic metabolite in fructose-fed mice. …”

Datasheet1_Acquired von Willebrand syndrome (AVWS) type 2, characterized by decreased high molecular weight multimers, is common in children with severe pulmonary hypertension (PH)... by Ivonne Wieland (14112981)

“…Notably, 3 of 5 patients (60%) with normal VWF:Ac/VWF:Ag ratio >0.7 had abnormal VWF multimers, indicating AVWS type 2. …”

Muscle development. by Jérémy Grandhaye (8703483)

(a) As the condensate is being squeezed in the <em>xy</em> plane, the peak value of the mathcal {F}_z increases with respect to ω_⊥/ω, where ω_⊥ is the trapping... by Shu-Wei Song (557396)

“…<p><strong>Figure 5.</strong> (a) As the condensate is being squeezed in the <em>xy</em> plane, the peak value of the \mathcal {F}_z increases with respect to ω_⊥/ω, where ω_⊥ is the trapping frequency in the squeezing direction. …”

Marker of sperm quality. by Jérémy Grandhaye (8703483)

Structure and Bonding Properties of the Complex (η⁵-Diphenylfulvene)Mn(CO)₃⁺ by Martin A. O. Volland (3077121)

“…As a result of the bending of the exo methylene group the positive charge at the metal is increased and at C9 decreased.…”

Reduced Long-Term Relative Survival in Females and Younger Adults Undergoing Cardiac Surgery: A Prospective Cohort Study by Tone Bull Enger (668126)

“…The observed 30-day, 1-, 3- and 5-year mortality rates were 2.2%, 4.4%, 8.2% and 13.8%, respectively, and remained constant throughout the study period. …”

Metallization of a Hypervalent Radical Dimer: Molecular and Band Perspectives by John S. Tse (1321242)

“…Variable pressure and temperature conductivity measurements on the bisthiaselenazolyl radical dimer [<b>1a</b>]₂ have established the presence of a weakly metallic state over the pressure range 5−9 GPa. …”

Metallization of a Hypervalent Radical Dimer: Molecular and Band Perspectives by John S. Tse (1321242)

“…Variable pressure and temperature conductivity measurements on the bisthiaselenazolyl radical dimer [<b>1a</b>]₂ have established the presence of a weakly metallic state over the pressure range 5−9 GPa. …”

Metallization of a Hypervalent Radical Dimer: Molecular and Band Perspectives by John S. Tse (1321242)

“…Variable pressure and temperature conductivity measurements on the bisthiaselenazolyl radical dimer [<b>1a</b>]₂ have established the presence of a weakly metallic state over the pressure range 5−9 GPa. …”

Metallization of a Hypervalent Radical Dimer: Molecular and Band Perspectives by John S. Tse (1321242)

“…Variable pressure and temperature conductivity measurements on the bisthiaselenazolyl radical dimer [<b>1a</b>]₂ have established the presence of a weakly metallic state over the pressure range 5−9 GPa. …”

Metallization of a Hypervalent Radical Dimer: Molecular and Band Perspectives by John S. Tse (1321242)

“…Variable pressure and temperature conductivity measurements on the bisthiaselenazolyl radical dimer [<b>1a</b>]₂ have established the presence of a weakly metallic state over the pressure range 5−9 GPa. …”

Passive transfer of humanized anti-NS1 mAb 33D2 into DENV-inoculated mice decreases viral titer and NS1 level in mouse sera. by Sen-Mao Tien (12481273)

Elimination of persistent <i>P</i>. <i>c</i>. <i>chabaudi</i> infection decreases memory T cell numbers in <i>Icos</i>^-/- mice. by Leah E. Latham (8781863)

Table_2_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Image_2_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.tif by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Table_4_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Table_1_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Image_1_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.tif by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Table_3_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”